anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study was carried out to compare the impact of choline supplementation (available from two sources synthetic and natural) on various dosages in broilers. The mode of choline supplementation, via diet and additional sources, synthetic and natural, and the data of performance, carcass quality, blood parameters, and hepatic steatosis were compared. A total of 1050 day-old male Cobb 500 broiler chicks were randomly assigned to 10 treatments, using a completely randomized design model in a factorial scheme, with 6 replicates per treatment and 25 birds per replicate. Choline was supplemented using three sources: synthetic choline chloride 60% (CC), and two sources of natural choline A (NCA), and B (NCB). The Control treatment did not receive any choline supplementation. The diets were supplemented with low, intermediate and high doses of choline sources (400g/t, 800g/t, and 1200g/t of CC; 100g/t, 200g/t, and 300g/t of both NCA and NCB). Data analysis was performed using a factorial model to investigate the effects of choline supplementation (CC, NCA, NCB) and doses on the measured variables. Overall, the results indicated that the the performance of NCA was better than CC & NCB, specifically the dose of 100g/t of NCA outperformed MAR at 100g/t & CC at 400g/t, leading to a significant increase in body weight gain (85.66g & 168.84g respectively), and a noteworthy (9- & 12-point respectively) improvement in feed conversion ratio. Furthermore, NCA contributed to a reduction in steatosis when contrasted with various NCB & CC doses, likely due to the presence of curcumins and catechins in the natural choline source. These findings demonstrated that NCA supplementation yielded superior results compared to CC and NCB across both performance and liver health aspects in broilers aged 1 to 42 days. In conclusion, NCA can be used to replace the CC 60% without compromise on the zootechnical performance in broilers.
The present invention provides a small interference RNA molecule (SiRNA) for attacking human hepatitis B virus (HBV). The molecule is a double-chain RNA molecule, and the sequence of the molecule has at least 70% homological degree with a sequence (I) with the following characteristics: the lengths of a positive sense chain and an antisense chain are both 21 nucleotides; the 3' ends of the positive-sense chain and the antisense chain are respectively TT; basic groups on 19 nucleotides except for TT of the two chains are complemented into double chains. 19 nucleotide sequences of the positive-sense chain from the 5' end are completely consistent with 19 nucleotide sequences behind AA in No. 4 sequence of the sequence table; the proportion of the sum of the number of nucleotides whose basic groups are G and the number of nucleotides whose basic groups are C in each chain to the number of 19 nucleotides except for TT is larger than 25% and smaller than 75%. The antisense chain and the mutant of one nucleotide of the sequence (I) have no homology with known human genes and gene expression fragments. The SiRNA can be used for preparing medicines or preparations of preventing or treating hepatitis b and any disease relevant to hepatitis b virus infection.
In a study of intravenous infusion of iloprost on a dialysis-free day in adults with kidney failure receiving intermittent hemodialysis treatment (n = 7), the mean AUC 0-4hwas 230 pg*h/mL compared to 54 pg*h/mL in patients with kidney failure (n = 8) not requiring intermittent dialysis. The half-life was similar in both groups. The mean AUC 0-4hwas 48 pg*h/mL in normal subjects in a different study. In patients with renal impairment with eGFR less than 30 mL/min, the dose can be lowered to 0.25 ng/kg/minute if the patient cannot tolerate the starting dose of 0.5 ng/kg/minute [see Dosage and Administration ( 2.4)]. 

The effect of dialysis on the clearance of iloprost has not been evaluated. For patients requiring intermittent hemodialysis, consider iloprost administration after the end of hemodialysis. Alternatively, hemodialysis can be started at least one hour after the end of iloprost infusion.
The invention discloses a completely humanized neutralizing antibody for anti-rabies viruses. The antibody comprises a light chain and a heavy chain, wherein the amino acid sequence of a variable region of the light chain is shown in SEQ ID NO.3, and the amino acid sequence of a variable region of the heavy chain is shown in SEQ ID NO.4. According to the invention, an enzyme-linked immunological experiment and an immunoblotting experiment prove that the antibody can be combined with the specificity of rabies viruses. The neutralizing antibody disclosed by the invention can effectively detect rabies viruses, and the rabies-virus detection sensitivity thereof reaches 0.06 ng/ml. The antibody disclosed by the invention can be used for preparing kits and drugs for detecting and treating the rabies. The invention discloses a preparation method of the antibody. The antibody disclosed by the invention is a completely humanized antibody which is safe in use, has no side effect, and can be used for mass production.
With the switch from trivalent to bivalent oral poliovirus vaccine (OPV) in 2016, the Global Polio Eradication Initiative (GPEI) is recommending inactivated poliovirus vaccine (IPV) use as one of the potential strategies to respond to outbreaks of type 2 wild type and/or circulating vaccine-derived polioviruses. However, the current global inactivated poliovirus vaccine (IPV; 0.5 mL, full-dose) supply shortage dramatically limits the number of doses available for an effective outbreak response. Therefore, GPEI has proposed use of intradermal administration of a booster of fractional IPV (fIPV; 0.1 mL, one-fifth the full-dose) as a dose-sparing strategy to increase the number of children vaccinated and stretch IPV supplies. No study has compared immunogenicity of a fIPV booster in children previously vaccinated with a single IPV. Furthermore, the IPV shortage has led to reconsideration of fIPV use in routine immunization programs. Previous studies found that in one and two dose head-to-head comparisons, fIPV induced a lower proportion of seroconversion and antibody responses than IPV. However, recent studies of seroconversion and priming suggest two fIPV given at least eight weeks apart may be more immunogenic than one IPV. Because of these findings and the global IPV shortage, the most recent WHO position paper suggests that countries consider administering two fIPV at 6 and 14 weeks of age as an alternative to one IPV after the OPV2 cessation in April 2016. However, no trial has conducted a direct comparison of the immunogenicity of IPV at 14 weeks of age with that of fIPV at 6 and 14 weeks of age.

The immunogenicity of rotavirus (RV) vaccines will also be assessed when given concomitantly with IPV/fIPV. Currently, WHO recommends either of two licensed, live attenuated oral rotavirus vaccines for all children worldwide: the pentavalent RotaTeq (RV5) and monovalent Rotarix (RV1). Many lower income countries where IPV is being introduced are also poised to introduce rotavirus vaccine in the coming years. The first dose of OPV interferes with RV vaccines and RV vaccines may be more immunogenic when delivered with IPV compared with OPV. The proposed study presents an opportunity to compare the two and three dose responses of RV1 and RV5 when delivered with IPV compared with previous studies in Bangladesh when co-administered with OPV.

In addition, recent studies have suggested that host genetic factors (i.e., Secretor status and Lewis and salivary ABO blood group phenotype) mediate susceptibility to rotavirus infection. More precisely, non-secretors (i.e., children lacking a functional fucosyl transferse-2 \[FUT2\] gene) have substantially reduced risk of rotavirus infection of certain genotypes. Furthermore, certain rotavirus genotypes infected mainly Lewis negative children, independent of secretor status. In addition, blood group antigen status has been proposed to be associated with infection (or lack of infection) by particular rotavirus genotypes. The proposed trial will assess whether Secretor status, Lewis and salivary ABO blood group phenotype are also associated with vaccine response.
Patients who are randomized to this strategy will receive revascularization of the culprit lesion and guided by functional assessment on all non-culprit lesions. Functional evaluation is mandatory for all stenosis with diameter stenosis % between 50 and 90% at visual estimation. Revascularization must be guided by functional assessment on all vessels. The system utilized to obtain functional evaluation is left to Operator's discretion. PCI is allowed only if functional evaluation is positive according to the threshold of the chosen functional system. It is suggested to achieve functional complete revascularization within the index procedure, while it is mandatory to obtain it within the index hospitalization.
Disclosed is an ultrasonically-enhanced continuous and large-scale production method for nano-formulations. Specifically disclosed is a preparation system for continuous production of nano-formulations, comprising (a) a first pipe, (b) a second pipe, (f) an ultrasonic device, (c) a combined pipe and (e) a (fluid) outlet thereof. The first pipe and the second pipe are connected to the combined pipe. A first phase solution enters the combined pipe through a first pipe outlet, and a second phase solution enters the combined pipe through a second pipe outlet. The ultrasonic device acts on the part or the whole of the combined pipe. The first phase solution and the second phase solution are turbulently mixed in the combined pipe to form a combined phase, and flow out through the outlet of the combined pipe. The preparation system and the preparation method of the present invention can remarkably improve the entrapment efficiency of nano-drugs, and improve the uniformity of the particle size of nano-particles.
This study is a six week, double-blinded, placebo-controlled study, involving thirty participants, males and females, aged 45-75 years receiving physiotherapy treatment for OA of the lumbar spine at a specific and identified physiotherapist's private practice. A poster advert , placed in the physiotherapist's private practice, with permission , will be used to recruit participants. Individuals who respond to the poster advert will be provided with information pertaining to the study and will be requested to sign a consent form . A screening examination forming part of the inclusion criteria will be conducted by the researcher. Participants meeting the inclusion criteria will be randomly allocated to a treatment or control group; both groups will receive a standard physiotherapy treatment once every two weeks from the physiotherapist. Treatment will consist of lower back classic massage, lumbar joint manipulation, the application of a hot pack and each treatment session will last for 30 minutes. In addition to physiotherapy treatment, participants will be allocated, either a placebo or the homoeopathic complex, with instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one. This will comprise of 168 tablets, 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine.

Four consultations will take place at the physiotherapist's private practise. At the first consultation after having divided participants into the treatment and control group, participants will complete the Oswestry Low Back Pain Disability Questionnaire with the researcher's assistance. The researcher will assess the lumbar spine's ROM using the attraction tape measurement. Participants will be provided with 1 copy of the VAS pain scale with spaces to rate their pain every evening for 14 days and 56 tablets. During the second and third consultation, copies of the VAS pain scale will be collected as well as medication containers, to assess participant's compliance in taking their medication. A subjective and physical examination will be conducted, the Oswestry Low Back Pain Disability Questionnaire will be completed and ROM for the lumbar spine will be measured. Participants will receive tablets and copies of the VAS pain scale. On the forth consultation the researcher will conduct the last subjective and physical examination, complete the last Oswestry Low Back Pain Disability Questionnaire and conduct the last ROM measurement using the attraction tape measurement. The last copies of the VAS pain scale and medication containers will be collected.

A subjective and physical examination, Oswestry Low Back Pain Disability Questionnaire, the retraction tape measurement for ROM and the VAS pain scale will be used to collect data and analysed statistically using the Wilcoxon signed test or t-test within groups and t-test (parametric) or Mann-Whitney U (non-parametric) on between groups
* Thaw ZOLGENSMA before use. The contents of the ZOLGENSMA kit will thaw in approximately 16 hours if placed in a refrigerator, or in approximately 6 hours if placed at room temperature. If thawed in a refrigerator, remove from refrigerator on day of dosing.
  * When thawed, ZOLGENSMA is a clear to slightly opaque, colorless to faint white liquid, free of particles. Visually inspect vials for particulate matter and discoloration prior to infusion. Do not use vials if particulates or discoloration are present.
  * DO NOT SHAKE.
  * Draw the appropriate dose volume from all vials into a syringe, remove air from the syringe, cap the syringe, and deliver the syringe at room temperature to the patient infusion location.
  * Use ZOLGENSMA within 8 hours of drawing into syringe. Discard the vector-containing syringe if the drug is not infused within the 8-hour timeframe.
  * DO NOT REFREEZE.
This invention relates to a method for the biochemical treatment of persistent pain disorders by inhibiting the biochemical mediators of inflammation in a subject comprising administering to said subject any one of several combinations of components that are inhibitors of biochemical mediators of inflammation. Said process for biochemical treatment of persistent pain disorders is based on Sota Omoigui's Law, which states: ‘The origin of all pain is inflammation and the inflammatory response’. Sota Omoigui's Law of Pain unifies all pain syndromes as sharing a common origin of inflammation and the inflammatory response. The various biochemical mediators of inflammation are present in differing amounts in all pain syndromes and are responsible for the pain experience. Classification and treatment of pain syndromes should depend on the complex inflammatory profile. A variety of mediators are generated by tissue injury and inflammation. These include substances produced by damaged tissue, substances of vascular origin as well as substances released by nerve fibers themselves, sympathetic fibers and various immune cells. Biochemical mediators of inflammation that are targeted for inhibition include but are not limited to: prostaglandin, nitric oxide, tumor necrosis factor alpha, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8, histamine and serotonin, substance P, Matrix Metallo-Proteinase, calcitonin gene-related peptide, vasoactive intestinal peptide as well as the potent inflammatory mediator peptide proteins neurokinin A, bradykinin, kallidin and T-kinin.
Seborrhoeic dermatitis (SD) is a common chronic papulosquamous dermatosis, affecting 2% to 10% of the adult population, mainly those between the ages of 20 and 50 years with a male bias. The affected skin appears erythematous and oedematous, covered with yellow-brown scales, and is often accompanied by pruritus. It typically affects areas containing sebaceous glands, particularly the scalp, ears, face, chest, and intertriginous areas. SD has a chronic course, and relapse is common. Therefore, therapy is directed toward reducing the symptoms or aggravating factors of SD, such as loosening and removal of scales and crusts, inhibition of yeast colonization, control of secondary infection, and reduction of erythema and pruritus. Standard topical treatments for SD include corticosteroids and anti-mycotic medications. However, the chronic use of topical corticosteroids particularly on the face could result in undesirable outcomes, such as telangiectasia, atrophy, striae, peri-oral dermatitis, or tachyphylaxis, and early relapse after discontinuation of treatment. SD relapse prevention strategies have not yet been established, so the investigators suspected that intermittent use of tacrolimus ointment can be effective in preventing SD relapse.
It is planned to include 26 patients in the control group. Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the individuals in the control group in the first week of the 7-week research programme. Data will be collected by face-to-face interview with the patients. Individuals in the control group will not be given any training by the researcher. Individuals in the control group will be given an appointment for the post-test after seven weeks. At the end of seven weeks, individuals in the control group will be asked to fill in the Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) again.
Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
PURPOSE:To obtain a reagent capable of being used in the simple and easy self- diagnosis of pregnancy judgement and good in storage stability, by hermetically sealing a glass ampule filled with a dose of a polystyrene latex reagent sensitized with anti-human chorionic gonadotropin (anti-HCG) antibody. CONSTITUTION:Anti-HCG serum obtained by immunizing a rabbit with a mixture of a physiological saline solution of purified HCG and perfect Freund's adjuvant is subjected to salting-out to obtain a gamma-globulin fraction and, after dialysis, the dialysate is dissolved in a phosphate buffer solution and polystyrene latex and bovine serum albumin are added thereto. After incubation, the reation mixture is subjected to centrifugal separation and the obtained precipitate is suspended in a glycine buffer solution in a concn. of 1% to obtain an anti-HCG sensitized latex reagent. This reagent is distributed in a glass ampule at every 30+ or -3mul and, after vacuum lyophilization, N2-gas is sealed in said glass ampule to hermetically close the same by melting. After this ampule is opened, a definite amount (about 60-100ml) of a specimen (urine) is put therein and shaken. If agglutination reaction is generated within about several sec-3min, positivity is proved. If the latex is colored, agglutination can be clearly detected.
The safety and effectiveness of desoximetasone topical spray have not been established in pediatric patients for the treatment of plaque psoriasis. Desoximetasone topical spray is not recommended for use in patients less than 18 years of age due to the high incidence of HPA axis suppression observed [see Warnings and Precautions (5.1)].

Hypothalamic-Pituitary Adrenal (HPA) Axis Suppression

The HPA axis suppression potential of desoximetasone topical spray was assessed in an open-label, sequential cohort, safety trial in 129 subjects 2 years to less than 18 years of age with moderate to severe plaque psoriasis defined as a Physician Global Assessment (PGA) score of ≥3 with involvement of at least 10% of their body surface area (excluding the face and scalp). In total, 100 pediatric subjects were evaluated for HPA axis function via cosyntropin stimulation testing at baseline and following 4 weeks of twice daily application of desoximetasone topical spray. Overall, 36% of pediatric subjects 2 years to less than 18 years of age demonstrated HPA axis suppression defined as a serum cortisol level ≤ 18 mcg/dL 30-minutes post cosyntropin stimulation. The proportion of subjects demonstrating HPA axis suppression was 35.0% in Cohort 1 (12 years to less than 18 years of age) and 43.3% in Cohort 2 (6 years to less than 12 years of age). Trial enrollment in the youngest cohort (2 years to less than 6 years of age) was discontinued early due to high incidence of HPA axis suppression observed in the two oldest cohorts (6 years to less than 18 years of age) [see Clinical Pharmacology (12.2)].

Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse reactions including striae have been reported with inappropriate use of topical corticosteroids in infants and children.

HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
PURPOSE:The titled pharmaceutical, consisting of an adhesive layer containing specific hollow fibers containing a drug in the hollow parts thereof and specific support and having high safety and excellent effect on sustained release of the drug. CONSTITUTION:A sustained release pharmaceutical for percutaneous administration obtained by containing an adhesive layer prepared by containing a drug, e.g. coronary vasodilator, antiarrythmic agent, drug for angina pectoris, hypotensive agent, etc., in hollow fibers, e.g. polyester, etc., having through-holes in the outer peripheral direction and a support containing a film having 4.9-0.5mu thickness, e.g. polyolefin, polyester, polyamide, etc., as part or whole thereof. If the thickness of the above-mentioned support attains >=4.9mu, the flexibility of the pharmaceutical becomes inferior and condition of contact dermatitis is increased. If the thickness attains <=0.5mu, the film is broken by slight external force and the safety of the pharmaceutical is deteriorated. The above-mentioned pharmaceutical may contain an absorption adjuvant, etc., as necessary.